Page 118 - Pagetit
P. 118

4. PSYCHOPHARMACOLOGY OF DEPENDENCE FOR DIFFERENT DRUG CLASSES




                     Fig.4.3   Comparison of dopamine D2 receptor binding in the brains of a
                               control subject and a person with methamphetamine
                               dependence































                     Source: Volkow et al., 2001a. Reproduced with permission from the publisher.

                     similar to these substances. Ecstasy is classifiable as a hallucinogen, due to
                     the potential induction of hallucinations if used in extremely high doses
                     (American Psychiatric Association, 1994; WHO, 2001). As the subjective effects
                     of MDMA in humans are not the same as those produced by LSD and because
                     the drug does not present similar structure or pharmacological activity to
                     hallucinogens, the term “entactogens”, meaning “entering in contact with
                     yourself ” (Nichols, 1986; Morgan, 2000) was proposed to define a new
                     pharmacological class. As the understanding of the drug effects increases,
                     its classification will be more accurate. Use of ecstasy has recently been
                     associated with the global trend of dance parties (or “raves”) and “techno”
                     music (WHO, 2001).
                        Psychostimulant effects of MDMA are observed 20–60 minutes after oral
                     ingestion of moderate doses (50–125 mg) of ecstasy and last from 2–4 hours
                     (Grispoon & Bakalar, 1986). Peak plasma levels of ecstasy occur 2 hours after
                     oral administration, and only residual levels are found 24 hours after the last
                     dose (Verebey, Alrazi & Jafre, 1988; Cami et al., 1997). MDMA has a non-linear
                     pharmacokinetic profile: consumption of elevated doses of the substance
                     may produce disproportional elevation of plasma levels of ecstasy (Cami et
                     al., 1997; de la Torre et al., 2000).


                                                     97




          Chapter_4                97                              19.1.2004, 11:43
   113   114   115   116   117   118   119   120   121   122   123